Ardana has reported that its experimental testosterone cream had passed a key intermediate clinical trial involving 42 patients diagnosed with male hypogonadism.
The company's Phase II study involved three groups, each consisting of 14 patients, who received in random order a single application of the testosterone cream at varying dose levels or a placebo treatment. Both placebo and active cream were applied to one upper arm only, the firm added.
The condition -- also known as testosterone deficiency -- refers to the inability of the testicles to produce testosterone, sperm or both. Hypogonadism can result in sexual problems, decreased beard and body hair, breast enlargement, and muscle loss.